Michaeland1...To me the patent situation is what gives AMBS the most leverage.
Amarantus owns composition of matter and method of use patents for MANF, including claims for use of MANF as a protein therapy, gene therapy and as an adjuvant within the context of cell therapy.
Very good sign if a partnership should be done with AMBS in the future. Strong leveraging point.